PDE5A and Hypertension: This case highlights the need for caution when prescribing PDE5 inhibitors in patients with predisposing cardiovascular conditions that can contribute to increasing left ventricular end-diastolic pressure [3] or PCWP, such as LBBB and uncontrolled hypertension.